Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Frank Neumann

Showing results (81-90 of 118) with videos related to

Pageof 12
Sort By:
Frontiers in Oncology|December 7, 2020
Integration of the B-Cell Receptor Antigen Neurabin-I/SAMD14 Into an Antibody Format as New Therapeutic Approach for the Treatment of Primary CNS LymphomaMoritz Bewarder, Maximilian Kiefer, Clara Moelle, et al.
International Journal of Cancer|March 3, 2004
Expression of cancer testis antigens in pancreatic carcinoma cell lines, pancreatic adenocarcinoma and chronic pancreatitisBoris Kubuschok, Xiaoxiun Xie, Ralf Jesnowski, et al.
Oncogene|April 5, 2005
Distinct molecular phenotype of malignant CD34(+) hematopoietic stem and progenitor cells in chronic myelogenous leukemiaRalf Kronenwett, Ulf Butterweck, Ulrich Steidl, et al.
Scientific Reports|April 26, 2024
Hyper-N-glycosylated SEL1L3 as auto-antigenic B-cell receptor target of primary vitreoretinal lymphomasMichelle Elbert, Frank Neumann, Maximilian Kiefer, et al.
Nature Cancer|January 6, 2026
Axicabtagene ciloleucel in combination with rituximab for refractory large B cell lymphoma: the phase 2, single-arm ZUMA-14 trialPaolo Strati, Lori Leslie, Parveen Shiraz, et al.
British Journal of Haematology|May 21, 2026
Plasmacytic markers as immunotherapeutic targets for primary CD20-negative aggressive B-cell lymphomasFrank Neumann, Claudia Schormann, Onur Cetin, et al.
Experimental Hematology|November 9, 2002
Reliable engraftment, low toxicity, and durable remissions following allogeneic blood stem cell transplantation with minimal conditioningGuido Kobbe, Peter Schneider, Manuel Aivado, et al.
Cancer Immunology, Immunotherapy : CII|April 18, 2020
Characterization of an HLA-restricted and human cytomegalovirus-specific antibody repertoire with therapeutic potentialMoritz Bewarder, Gerhard Held, Lorenz Thurner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 13, 2025
Axicabtagene Ciloleucel in Combination With Atezolizumab in Patients With Refractory Diffuse Large B-cell Lymphoma: The Phase 1/2 ZUMA-6 TrialCaron A Jacobson, Jason R Westin, David B Miklos, et al.
International Journal of Molecular Sciences|December 17, 2024
Cytomegalovirus-Specific T-Cell-Receptor-like Antibodies Target In Vivo-Infected Human Leukocytes Inducing Natural Killer Cell-Mediated Antibody-Dependent Cellular CytotoxicityMoritz Bewarder, Konstantinos Christofyllakis, Milena Petersen, et al.
Pageof 12

Showing results (81-90 of 118) with videos related to

Sort By:
Pageof 12
Frontiers in Oncology|December 7, 2020
Integration of the B-Cell Receptor Antigen Neurabin-I/SAMD14 Into an Antibody Format as New Therapeutic Approach for the Treatment of Primary CNS LymphomaMoritz Bewarder, Maximilian Kiefer, Clara Moelle, et al.
International Journal of Cancer|March 3, 2004
Expression of cancer testis antigens in pancreatic carcinoma cell lines, pancreatic adenocarcinoma and chronic pancreatitisBoris Kubuschok, Xiaoxiun Xie, Ralf Jesnowski, et al.
Oncogene|April 5, 2005
Distinct molecular phenotype of malignant CD34(+) hematopoietic stem and progenitor cells in chronic myelogenous leukemiaRalf Kronenwett, Ulf Butterweck, Ulrich Steidl, et al.
Scientific Reports|April 26, 2024
Hyper-N-glycosylated SEL1L3 as auto-antigenic B-cell receptor target of primary vitreoretinal lymphomasMichelle Elbert, Frank Neumann, Maximilian Kiefer, et al.
Nature Cancer|January 6, 2026
Axicabtagene ciloleucel in combination with rituximab for refractory large B cell lymphoma: the phase 2, single-arm ZUMA-14 trialPaolo Strati, Lori Leslie, Parveen Shiraz, et al.
British Journal of Haematology|May 21, 2026
Plasmacytic markers as immunotherapeutic targets for primary CD20-negative aggressive B-cell lymphomasFrank Neumann, Claudia Schormann, Onur Cetin, et al.
Experimental Hematology|November 9, 2002
Reliable engraftment, low toxicity, and durable remissions following allogeneic blood stem cell transplantation with minimal conditioningGuido Kobbe, Peter Schneider, Manuel Aivado, et al.
Cancer Immunology, Immunotherapy : CII|April 18, 2020
Characterization of an HLA-restricted and human cytomegalovirus-specific antibody repertoire with therapeutic potentialMoritz Bewarder, Gerhard Held, Lorenz Thurner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 13, 2025
Axicabtagene Ciloleucel in Combination With Atezolizumab in Patients With Refractory Diffuse Large B-cell Lymphoma: The Phase 1/2 ZUMA-6 TrialCaron A Jacobson, Jason R Westin, David B Miklos, et al.
International Journal of Molecular Sciences|December 17, 2024
Cytomegalovirus-Specific T-Cell-Receptor-like Antibodies Target In Vivo-Infected Human Leukocytes Inducing Natural Killer Cell-Mediated Antibody-Dependent Cellular CytotoxicityMoritz Bewarder, Konstantinos Christofyllakis, Milena Petersen, et al.
Pageof 12